熱門資訊> 正文
Allarity Therapeutics开始招募开发Senoparib的II期试验
2026-02-03 21:09
- This is the first trial combining Allarity's stenoparib with another anti-cancer agent
- Stenoparib's favorable safety profile supports potential for use in combination regimens
- Trial is fully funded by the U.S. Department of Veterans Affairs and is open to enrollment at 11 VA sites throughout the US
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。